Skip to the page

Data / Drug companies / Mylan Institutional LLC

Mylan Institutional LLC: 137 products in the FDA NDC directory, labeler code 67457

Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).

Mylan Institutional LLC (labeler code 67457) lists 137 products in the FDA National Drug Code Directory, covering 70 finished drugs by generic name. By type: 137 prescription drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on July 28, 2026.

The request: Watch Mylan Institutional LLC (FDA labeler code 67457): each new product listing and each discontinued product. $10 of work on sign-up, no card.

SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.

Labeler code
67457
Products in commercial distribution
137
Packages
142
Finished drugs by generic name
70
Prescription products
137
Over the counter products
0
Controlled substance products
Schedule II 4
Flagged as original packager
130 of 130 products that carry the flag
Started marketing in the last 12 months
6
Products with a marketing end date set
4
Earliest marketing start
April 4, 1978
openFDA record search
api.fda.gov

Products by marketing category

Share of the company's products in commercial distribution.

Marketing categoryProductsShare
Generic drugs (ANDA)11181%
New drug applications (NDA)1813.1%
Authorized generics (NDA)42.9%
Other unapproved drugs21.5%
Biologics (BLA)21.5%

Products by type

TypeProductsShare
Prescription drugs137100%

Drugs it lists

Finished drugs by generic name, with how many companies list each.

DrugProductsCompanies listing it
Fondaparinux sodium86
Vancomycin hydrochloride739
Octreotide acetate611
Dexamethasone sodium phosphate625
Adenosine415
Levetiracetam487
Zoledronic acid318
Triamcinolone acetonide377
Leucovorin calcium318
Granisetron hydrochloride38
Docetaxel anhydrous35
Gemcitabine hydrochloride36
Naloxone hydrochloride340
Famotidine3138
Iron sucrose35
Remifentanil hydrochloride34
Eptifibatide39
Sodium nitroprusside214
Daptomycin225
Oxaliplatin216
Vecuronium bromide210
Epoprostenol24
Haloperidol decanoate216
Tetradecyl hydrogen sulfate (ester)21
Tobramycin241
Esmolol hydrochloride in sodium chloride24
Sugammadex222
Trastuzumab24
Pamidronate disodium22
Ropivacaine hydrochloride220
Etomidate210
Dexmedetomidine hydrochloride221
Methadone hydrochloride121
Clonidine hydrochloride145
Rocuronium bromide125
Moxifloxacin hydrochloride120
Posaconazole129
Magnesium chloride12
Esmolol hydrochloride112
Decitabine118
Melphalan hydrochloride114
Tranexamic acid139
Fomepizole16
Calcitonin salmon113
Norepinephrine bitartrate125
Palonosetron hydrochloride111
Haloperidol lactate16
Doxycycline163
Fosaprepitant110
Acetaminophen1214
Allopurinol154
Thiamine hydrochloride118
Mycophenolate mofetil137
Prochlorperazine edisylate116
Amphotericin b liposome11
Cidofovir anhydrous11
Docetaxel121
Acetazolamide sodium13
Paclitaxel120
Amiodarone hydrochloride135
Dexmedetomidine111
Bivalirudin113
Medroxyprogesterone acetate123
Dimethyl sulfoxide12
Isosulfan blue17
Fluphenazine decanoate19
Doxorubicin hydrochloride120
Argatroban112
Rifampin113
Ferric carboxymaltose13

Dosage forms

Dosage formProductsShare
Injection, solution6849.6%
Injection, powder, lyophilized, for solution2619%
Injection2014.6%
Injection, solution, concentrate75.1%
Kit53.6%
Injection, powder, lyophilized, for suspension53.6%
Injection, suspension42.9%
Solution10.7%
Irrigant10.7%

Pharmacologic classes

FDA established pharmacologic classes of its products.

Newest products

By marketing start date.

ProductProduct NDCDosage formMarketing categoryMarketing start
Sugammadex67457-970Injection, solutionGeneric drugs (ANDA)July 28, 2026
Sugammadex67457-969Injection, solutionGeneric drugs (ANDA)July 28, 2026
Ferric Carboxymaltose67457-797Injection, solutionGeneric drugs (ANDA)July 1, 2026
Octreotide acetate67457-762KitGeneric drugs (ANDA)January 28, 2026
Octreotide acetate67457-759KitGeneric drugs (ANDA)January 28, 2026
Octreotide acetate67457-756KitGeneric drugs (ANDA)January 28, 2026
Paclitaxel67457-937Injection, powder, lyophilized, for suspensionGeneric drugs (ANDA)October 9, 2025
Iron Sucrose67457-957Injection, solutionGeneric drugs (ANDA)August 8, 2025
Iron Sucrose67457-639Injection, solutionGeneric drugs (ANDA)August 8, 2025
Iron Sucrose67457-638Injection, solutionGeneric drugs (ANDA)August 8, 2025
Amphotericin B liposome67457-926Injection, powder, lyophilized, for suspensionGeneric drugs (ANDA)August 6, 2025
Epoprostenol67457-588Injection, powder, lyophilized, for solutionGeneric drugs (ANDA)September 25, 2024
Epoprostenol67457-587Injection, powder, lyophilized, for solutionGeneric drugs (ANDA)September 25, 2024
Posaconazole67457-665SolutionGeneric drugs (ANDA)March 22, 2024
Ropivacaine hydrochloride67457-799Injection, solutionGeneric drugs (ANDA)March 18, 2024
Ropivacaine hydrochloride67457-798Injection, solutionGeneric drugs (ANDA)March 18, 2024
Daptomycin67457-941Injection, powder, lyophilized, for solutionGeneric drugs (ANDA)November 27, 2023
Triamcinolone acetonide67457-623Injection, suspensionGeneric drugs (ANDA)May 8, 2023
Triamcinolone acetonide67457-622Injection, suspensionGeneric drugs (ANDA)May 8, 2023
Triamcinolone acetonide67457-621Injection, suspensionGeneric drugs (ANDA)May 8, 2023
Naloxone Hydrochloride67457-992Injection, solutionGeneric drugs (ANDA)December 2, 2022
Mycophenolate Mofetil67457-386Injection, powder, lyophilized, for solutionGeneric drugs (ANDA)January 26, 2021
Acetaminophen67457-940Injection, solutionGeneric drugs (ANDA)December 7, 2020
Dexmedetomidine hydrochloride67457-925Injection, solutionGeneric drugs (ANDA)November 13, 2020
Dexmedetomidine hydrochloride67457-924Injection, solutionGeneric drugs (ANDA)November 13, 2020

CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.